Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK2 | Q13002 | 3/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 4/20 | 0.43 |
| ▸ | AS3MT | Q9HBK9 | 3/20 | 0.38 |
| ▸ | PFKFB2 | O60825 | 3/20 | 0.38 |
| ▸ | PFKFB1 | P16118 | 3/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.38 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10096329 | 0.94 | PGR (0.46) | GRIK2GRIK1CYP11B2PGRAS3MT | |
| SCHEMBL10096281 | 0.92 | GRIK2 (0.44) | GRIK2GRIK1PGRAS3MTPFKFB2 | |
| SCHEMBL10095306 | 0.92 | CYP11B2 (0.46) | GRIK2GRIK1CYP11B2PGRMEN1 | |
| SCHEMBL10096286 | 0.90 | PGR (0.42) | GRIK2GRIK1CYP11B2PGRAS3MT | |
| SCHEMBL10095751 | 0.89 | CYP11B2 (0.55) | GRIK2GRIK1CYP11B2PGRAS3MT | |
| SCHEMBL10096287 | 0.88 | GRIK2 (0.41) | GRIK2GRIK1CYP11B2AS3MTPFKFB2 | |
| SCHEMBL10095937 | 0.87 | GRIK2 (0.51) | GRIK2GRIK1CYP11B2PGRAS3MT | |
| SCHEMBL10095794 | 0.87 | PGR (0.46) | GRIK2GRIK1CYP11B2PGRMEN1 | |
| SCHEMBL10095873 | 0.87 | CYP11B2 (0.44) | GRIK2GRIK1CYP11B2PGRMEN1 | |
| SCHEMBL10095877 | 0.86 | AR (0.53) | CYP11B2PGRAS3MTPFKFB2PFKFB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7781478-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781478-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | GRIK2 3701/4885GRIK1 3372/4885CYP11B2 808/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | GRIK2 2948/4885GRIK1 2562/4885CYP11B2 1863/4885 |
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | GRIK2 2948/4885GRIK1 2562/4885CYP11B2 1863/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | GRIK2 4491/4885GRIK1 4307/4885CYP11B2 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.